מכפיל מחיר לרווח Annovis Bio Corp (ANVS)

The quotes below illustrate the price action of Annovis Bio, Inc. (ANVS), whose P/E ratios stand at -0.80. Annovis Bio, Inc. (ANVS) is implementing energy-saving technologies and emission filtration in its laboratories to comply with ESG standards. Business growth relies on the success of buntianesan in the therapy of degenerative brain diseases and FDA approval. High volunteer interest in trials creates a closed patient environment, determining the pace of commercialization.
פילוחי מדדים מקיפים ואנליטיקה עבור annovisbio.com (ANVS)

The specifics of Annovis Bio, Inc. (ANVS) clinical trials eliminate operating leverage, turning the company's quarterly P/E into an indicator of pure capital burn amid linear cost growth. This metric is calculated as the ratio of market capitalization to net income, measuring the cost of one dollar of earnings and allowing investors to assess the extent of the premium paid for future expectations regarding neuro-drugs.